31.03.17: Not intended for U.S. and UK Media - American Association for Cancer Research (AACR) 108th Annual Meeting:
Phase II Copanlisib Data Show Durable Tumor Response in Indolent Non-Hodgkin's LymphomaCopanlisib achieves objective tumor response rate of 59% in indolent Non-Hodgkin's Lymphoma (iNHL) patients with a manageable safety profile in CHRONOS-1 study / Data to be featured in an oral presentation in a Clinical Trials session on April 4 at AACR / Bayer in discussion with the U.S. Food and Drug Administration regarding a filing for an accelerated approval of copanlisib in follicular lymphoma (FL), a subset of iNHL / Copanlisib granted Fast Track Designation in the U.S. for FL and Orphan Drug Designation in the U.S. for FL and marginal zone lymphomamehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Food and Drug Administration (FDA) | Lymphoma | Non-Hodgkin's Lymphoma | Oral Cancer | Pharmaceuticals | Study